CH

CHEIL BIO CO., LTD.

Manufactures veterinary medicines and feed additives for livestock, aquatic animals, and pets.

052670 | KO

Overview

Corporate Details

ISIN(s):
KR7052670007
LEI:
Country:
South Korea
Address:
경기 안산시 목내동 456-2, 안산시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cheil Bio Co., Ltd. is a manufacturer of animal medicines and veterinary products focused on improving the health of livestock, aquatic animals, and pets. The company develops, produces, and distributes a wide range of pharmaceuticals, including antibiotics, nutritional supplements, probiotics, and functional feed additives. Leveraging its research and development capabilities, Cheil Bio aims to provide high-quality, technologically advanced solutions for the poultry, swine, cattle, and fishery sectors. The company is committed to achieving global technological competitiveness through continuous innovation in biotechnology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Share Issue/Capital Change
[기재정정]액면주식ㆍ무액면주식전환결정
Korean 16.9 KB
2025-09-15 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(감자결정)
Korean 31.6 KB
2025-09-10 00:00
Legal Proceedings Report
주요사항보고서(소송등의제기)
Korean 5.7 KB
2025-08-26 00:00
Delisting Announcement
주권매매거래정지기간변경 (주식의 병합, 분할 등 전자등록 변경, 말소)
Korean 4.9 KB
2025-08-26 00:00
Legal Proceedings Report
횡령ㆍ배임혐의진행사항
Korean 8.4 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.0 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 780.5 KB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 14.1 KB
2025-08-01 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 14.4 KB
2025-08-01 00:00
Share Issue/Capital Change
[기재정정]액면주식ㆍ무액면주식전환결정
Korean 15.4 KB
2025-08-01 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(감자결정)
Korean 35.6 KB
2025-07-21 00:00
Legal Proceedings Report
횡령ㆍ배임혐의진행사항
Korean 6.9 KB
2025-07-18 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 9.6 KB
2025-07-18 00:00
Share Issue/Capital Change
액면주식ㆍ무액면주식전환결정
Korean 10.6 KB
2025-07-18 00:00
Share Issue/Capital Change
주요사항보고서(감자결정)
Korean 24.7 KB

Automate Your Workflow. Get a real-time feed of all CHEIL BIO CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CHEIL BIO CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CHEIL BIO CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.